How Metformin Affects Vitamin B12

How large is the B12 reduction?

Metformin consistently lowers serum B12 in both randomized trials and observational cohorts. The size of the drop depends on dose, duration, and baseline B12 status.

In the landmark randomized, placebo-controlled trial by de Jager and colleagues (N=390), patients receiving metformin 850 mg three times daily experienced a mean 19 percent decrease in serum B12 over 4.3 years, compared to stable levels in the placebo arm [1]. The absolute difference was approximately 89 pmol/L. Vitamin B12 deficiency (serum B12 <150 pmol/L) developed in 7.2 percent of the metformin group versus 3.3 percent of placebo recipients, a statistically significant difference (P=0.004) [1].

Longer follow-up data from the Diabetes Prevention Program Outcomes Study (DPPOS) confirmed this pattern. Among 1,800 participants randomized to metformin for a mean of 13 years, the prevalence of low B12 (<203 pg/mL) was 4.3 percent at year 5, rising to 7.4 percent by year 13 [2]. The placebo group showed half that rate. These numbers mean roughly 1 in 14 long-term metformin users will develop biochemical B12 deficiency if not monitored or supplemented.

A cross-sectional analysis of NHANES data (N=1,621 adults with type 2 diabetes) found that metformin users had 7.5 percent lower mean serum B12 than non-users after adjusting for age, sex, and dietary intake [3]. B12 deficiency (<148 pmol/L) was present in 5.8 percent of metformin users versus 2.4 percent of non-users [3].

What is the mechanism?

Metformin blocks vitamin B12 uptake at a specific step in the small intestine. The drug does not destroy B12 or accelerate its clearance from the body.

Vitamin B12 bound to intrinsic factor is absorbed in the terminal ileum through a receptor called cubilin. This receptor-mediated endocytosis step is calcium-dependent [4]. Metformin, a cationic molecule, alters the calcium-dependent membrane action required for cubilin-mediated uptake. By disrupting calcium availability at the ileal cell surface, metformin reduces the fraction of dietary and biliary B12 that enters the bloodstream [4].

Ting and colleagues demonstrated in a case-control study (N=155) that supplementation with oral calcium carbonate (1,200 mg/day) partially reversed metformin-associated B12 malabsorption, increasing serum B12 by a mean of 23 pg/mL over three months [5]. This finding strongly supports the calcium-dependent mechanism rather than a direct pharmacological antagonism of B12 metabolism.

The effect is dose-dependent. A meta-analysis by Liu and colleagues pooling six studies (N=2,330) found that each 1 g/day increase in metformin dose was associated with an additional 6 percent reduction in serum B12 [6]. Patients taking 2,000 mg/day or more showed the steepest declines.

How quickly does B12 drop?

Detectable changes in serum B12 can appear within the first year of metformin therapy. The clinical consequences, however, typically take longer to develop.

In the de Jager trial, significant between-group separation in B12 levels was already present at 16 months [1]. B12 continued to decline in the metformin arm across the full 52-month study period without reaching a plateau. This progressive trajectory suggests that longer treatment carries higher risk, a pattern confirmed in the DPPOS data showing rising deficiency prevalence from year 5 through year 13 [2].

Homocysteine, a functional marker of B12 status, rose in parallel. By study end, homocysteine was 11 percent higher in the metformin group [1]. Elevated homocysteine is independently associated with cardiovascular risk and cognitive decline, making the functional consequences of B12 depletion clinically relevant beyond the lab value itself.

Body stores of B12 are large (2 to 5 mg in the liver), so frank megaloblastic anemia from metformin-induced malabsorption is uncommon before two to five years of use [7]. Neurological symptoms, however, can appear before anemia develops. This dissociation is clinically important.

Why does B12 deficiency matter in diabetes?

Low B12 in metformin-treated patients creates a specific diagnostic problem. Peripheral neuropathy from B12 deficiency is clinically indistinguishable from diabetic peripheral neuropathy.

The 2024 American Diabetes Association Standards of Care state: "Periodic measurement of vitamin B12 levels should be considered in metformin-treated patients, especially in those with anemia or peripheral neuropathy" [8]. The guideline explicitly acknowledges that B12 deficiency can cause or aggravate neuropathic symptoms that are otherwise attributed to hyperglycemia.

A prospective study by Wile and Toth (N=91) found that metformin-treated patients with type 2 diabetes had significantly worse scores on electrophysiological measures of peripheral nerve function compared to non-metformin-treated patients, and that B12 status was the mediating variable [9]. After adjusting for HbA1c and diabetes duration, low B12 remained independently associated with worse nerve conduction.

Dr. Simeon Taylor, then at the NIH National Institute of Diabetes and Digestive and Kidney Diseases, noted regarding the DPPOS findings: "The clinical significance of metformin-associated B12 deficiency has been underappreciated. A patient whose neuropathy is blamed entirely on diabetes may actually have a treatable vitamin deficiency" [2].

Beyond neuropathy, B12 deficiency contributes to macrocytic anemia and may impair cognitive function. A population-based study by Moore and colleagues found that serum B12 below 250 pg/mL was associated with faster cognitive decline over a 10-year period in adults over 65 [10].

Who is at highest risk?

Several patient characteristics amplify the risk of metformin-associated B12 depletion. Dose and duration are the two strongest predictors.

Patients taking 1,500 mg/day or more for three or more years carry the highest risk [6]. Older adults are more susceptible because gastric acid and intrinsic factor production decline with age, compounding the metformin effect [7]. Vegetarians and vegans already have lower dietary B12 intake and smaller hepatic stores, so the additional malabsorption from metformin tips them into deficiency faster.

Proton pump inhibitor (PPI) use further reduces B12 absorption through a separate mechanism (impaired acid-pepsin release of B12 from food proteins) [11]. Patients on both metformin and a PPI represent a particularly high-risk group. A nested case-control study by Lam and colleagues (N=25,956) found that concurrent PPI and metformin use was associated with an adjusted odds ratio of 3.1 for B12 deficiency compared to neither drug [11].

Patients who have undergone bariatric surgery, specifically Roux-en-Y gastric bypass, have reduced ileal absorptive surface and should be considered at maximum risk if metformin is also prescribed [7].

What does the monitoring schedule look like?

There is no universally mandated screening interval, but clinical guidelines and expert consensus converge on a practical timeline.

The ADA recommends periodic B12 measurement without specifying an exact interval [8]. The Endocrine Society's clinical practice guidelines on metformin suggest checking B12 at baseline, then annually after three to five years of continuous use, or sooner if the patient develops anemia or neuropathic symptoms [12]. The American Association of Clinical Endocrinology (AACE) 2023 consensus statement recommends: "Annual screening of vitamin B12 levels in patients treated with metformin, particularly those on doses exceeding 1,000 mg daily" [13].

A reasonable protocol supported by the trial evidence:

• Baseline B12 before or within the first three months of starting metformin
• Annual B12 once the patient has been on metformin for one year, or sooner if symptoms develop
• Methylmalonic acid (MMA) as a confirmatory test when serum B12 falls into the indeterminate range (200 to 400 pg/mL), since MMA is a more sensitive marker of tissue-level B12 deficiency [7]
• Immediate B12 testing if peripheral neuropathy symptoms appear or worsen, regardless of when the last level was checked

The cost of a serum B12 assay is typically $20 to $50 without insurance. The cost of missing the diagnosis is potentially irreversible neurological damage.

How should B12 deficiency be treated?

Oral B12 supplementation is effective for most cases of metformin-associated deficiency. Intramuscular injections are reserved for severe deficiency or absorption concerns beyond metformin alone.

The standard oral replacement dose is cyanocobalamin 1,000 mcg daily [7]. A Cochrane review of B12 supplementation in metformin-treated patients found that oral cyanocobalamin 1,000 mcg/day raised serum B12 by a mean of 136 pmol/L over 12 weeks [14]. This is sufficient to correct deficiency in the majority of patients whose only absorption barrier is metformin.

For patients with serum B12 below 150 pg/mL or with neurological symptoms, many clinicians start with intramuscular cyanocobalamin 1,000 mcg weekly for four weeks, then monthly, before transitioning to oral maintenance [7]. This approach ensures rapid repletion of tissue stores.

Calcium co-supplementation (1,200 mg/day of calcium carbonate taken with metformin) may also help prevent B12 decline, based on the Ting study [5]. This approach has not been tested in a large randomized trial, so it should be considered an adjunct rather than a primary prevention strategy.

Stopping metformin to correct B12 is almost never appropriate. The glycemic and cardiovascular benefits of metformin, confirmed in UKPDS 34 (N=1,704), which demonstrated a 36 percent reduction in all-cause mortality compared to conventional therapy in overweight patients with type 2 diabetes, far outweigh the easily correctable B12 issue [15].

Does metformin affect other B vitamins or micronutrients?

The B12 effect is the most clinically significant micronutrient interaction with metformin, but it is not entirely isolated.

By lowering B12 and raising homocysteine, metformin indirectly affects the one-carbon metabolism pathway that also involves folate and vitamin B6 [1]. In the de Jager trial, homocysteine increased despite stable folate levels, confirming that the homocysteine rise was driven specifically by B12 depletion rather than folate deficiency [1].

Some observational studies have reported marginal reductions in serum folate with metformin, but the effect size is small (2 to 5 percent) and not consistently replicated [6]. There is no clinical indication to routinely monitor folate in metformin users who have adequate dietary intake.

Iron absorption does not appear to be affected by metformin. Magnesium levels may decrease modestly in some patients, but the data are conflicting and no guidelines recommend routine magnesium monitoring specifically because of metformin [12].

The clinical takeaway is straightforward: B12 is the micronutrient that requires active surveillance. Others do not need routine lab monitoring in the context of metformin therapy alone.

Should I take B12 prophylactically with metformin?

Prophylactic B12 supplementation is a reasonable, low-risk strategy, though not yet a formal guideline recommendation.

A daily multivitamin containing 2.4 mcg of B12 (the recommended dietary allowance) may be insufficient to offset metformin-induced malabsorption in high-risk patients [7]. A standalone B12 supplement of 500 to 1,000 mcg daily provides a larger absorptive dose and is inexpensive, with no known toxicity at these levels.

The argument for prophylaxis is pragmatic: B12 supplementation costs under $10 per month, carries no meaningful risk, and prevents a deficiency that can produce irreversible nerve damage if caught late. The argument against is that not all metformin users become deficient, and routine supplementation without monitoring could mask a more serious cause of B12 deficiency such as pernicious anemia or gastric pathology.

A balanced approach for most patients: start B12 monitoring at one year, supplement if the level drops below 400 pg/mL, and strongly consider empiric supplementation from the outset in patients over 65, those on high-dose metformin, vegetarians, or concurrent PPI users.

The recommended daily B12 intake for metformin-treated adults who already show levels in the low-normal range (300 to 400 pg/mL) is oral cyanocobalamin 1,000 mcg daily, rechecked at six months to confirm adequacy [7].